CATT: Ranibizumab and Bevacizumab Had Similar Effects on Visual Acuity Over 2 Years

Second-year results from the pivotal Comparison of Age-Related Macular Degeneration Treatment Trials (CATT) comparing bevacizumab (Avastin, Genentech) and ranibizumab (Lucentis, Genentech) found that the drugs are equivalent in treating neovascular age-related macular degeneration (AMD) when administered using similar...

Full Story →